On the fourth anniversary of New Zealand’s first COVID case it’s clear this is not a normal pandemic. Despite fatigue and indifference, New Zealand must heed the evidence and improve its response.
Articles on RSV
Displaying 21 - 40 of 51 articles
The TGA has just approved a vaccine against RSV for Australians over 60. Here’s where protection is up to for the youngest children, who are also at risk from the virus.
The current triple epidemic of respiratory viruses is affecting all age groups, prompting comparisons with the pre-COVID-19 era.
There are a number of pathogens which are reported to be causing the outbreak of respiratory illness in China.
Newly approved and updated vaccines are the best tools available to combat COVID-19, the flu and RSV, as infections and hospitalizations tick upward and cold and flu season gets underway.
Nearly 100,000 US children under age 5 are hospitalized each year for an RSV infection.
Even otherwise healthy children can end up in hospital with this winter respiratory virus.
The newly approved RSV vaccine could be rolled out by fall 2023, in time for the typical winter surge in RSV infections.
The first vaccine against respiratory syncytial virus is 83% effective.
Some of the prescription medications you’re taking may not mix with over-the-counter drugs.
Similar to the patterns seen with COVID-19, flu and RSV, HMPV is making a comeback after years of being repressed by people wearing masks and social distancing.
Here’s why it’s taken so long to develop a vaccine for respiratory syncytial virus and what we can expect next.
A combination of high demand and poor stock planning may explain current problems.
Evidence-based tools for dialectical behaviour therapy can help us manage family stressors during the virulent respiratory virus season.
While RSV can become severe for any child, it poses a particularly serious threat for the youngest babies and for high-risk children.
Nine children in the UK have now died from invasive group A strep. It’s important that parents know what to look out for.
As visits to emergency departments surge — and in some cases overwhelm hospitals — here are answers to frequently asked questions about Respiratory syncytial virus (RSV).
Family physicians are on the frontline of health care, and their observations and support can help us get through the upcoming winter season.
In 2020, with adult ICUs at risk of being overwhelmed, we wore masks and accepted restrictions. Now pediatric intensive care is at risk. Will leaders follow the evidence and tell us to mask up?
Respiratory syncytial virus may be common, but it can lead to severe infection in some children.
Top contributors
-
Adjunct Associate Professor of Epidemiology, University of California, Los Angeles
-
Professor of Infectious Diseases, Monash University
-
Paediatrician and Infectious Diseases Specialist; Clinical Researcher, University of Sydney
-
Paediatric Respiratory Physician, and Honorary Fellow Manager, Murdoch Children's Research Institute
-
Research Lead/Advanced Clinical Practitioner/Senior Research Fellow, University of Bradford
-
Associate Professor and Research Leader in Virology and Infectious Disease, Griffith University
-
Associate Professor of Pediatric Infectious Diseases, Baylor College of Medicine
-
General Practitioner, PhD Candidate, Bond University
-
Paediatrician, Infectious Diseases Physician and Clinical Microbiologist, The Kids Research Institute Australia, The University of Western Australia
-
Senior Research Officer, Murdoch Children's Research Institute
-
Professor of Health Service Operations, School of Pharmacy & Medical Sciences, University of Bradford
-
Professor of Nursing, Purdue University
-
Professor of Paediatrics and vaccinologist, Royal Childrens Hospital, University of Melbourne and Murdoch Childrens Research Institute (MCRI); Associate Dean International, University of Melbourne, Murdoch Children's Research Institute
-
Associate Professor of Paediatric Infectious Diseases, University of Southampton
-
Professor of Biostatistics and Epidemiology, Adelaide University